Page 3 - Torrent Pharmaceuticals

Torrent Pharma posts Rs 118 cr Q4 loss vs Rs 324 cr profit a year ago

The red line comes amid headwinds in EU operatopns and discontinuation of liquids business in the US; revenue, however, grows by 10%

19 Indian companies sign licensing pact for Pfizer's oral Covid drug

Torrent Pharma and Cadila Pharma sign licensing agreement with MPP to make and market the drug

Cadila, Torrent get licence to make generic version of Pfizer's Covid pill

Pharma firms enter into licensing agreement with Medicine Patent Pool to use nirmatrelvir compound for making PAXLOVID

Pharma stocks surge on positive cues from Nifty healthcare, Cipla up 6%

Outlook for Indian drug exporters turned positive on prospects of firm exports amid the ongoing geo-political scenario, said analysts

USFDA inspection of co's US plant completed successfully: Torrent Pharma

Torrent Pharmaceuticals Ltd on Thursday said its manufacturing facility at Levittown, Pennsylvania in the US has successfully completed inspection by the USFDA. The plant was inspected by USFDA (United States Food and Drug Administration) between December 6 and December 15, 2021. At the end of the inspection, no 'Form 483' was issued, the company said in a regulatory filing. As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. "It is a positive development for the company and is a reflection of our commitment to consistency in quality and compliance with regulatory standards," Torrent Pharmaceuticals said. According to information available on the company's website, the Levittown manufacturing facility is a part of Torrent Pharma's acquisition of Bio-Pharm, Inc (BPI) in 2018. It has ...

Domestic growth trajectory in key areas to remain strong for Torrent Pharma

More gains for the stock will depend on the recovery in the US market

Torrent Pharma Q1 net grows marginally by 3% as price erosion in US weighs

The company's revenues also grew in single digits at four per cent, from Rs 2,056 crore in Q1 of FY21 to Rs 2,134 crore in Q1 of FY22

Torrent Pharma's Q4 consolidated net profit up 3 pc at Rs 324 crore

Drug firm Torrent Pharma reported a 3.18 per cent rise in its consolidated net profit to Rs 324 crore for the quarter ended March 31, 2021

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

Robust performance of domestic biz to help Torrent Pharma outperform peers

Chronic-heavy portfolio, pharma market recovery boost shares

Torrent Pharma leaps 10%, nears 52-wk high as Q1 net profit jumps 49% YoY

In terms of markets, while its India revenues grew marginally by 2% on a year-on-year (YoY) basis to Rs 925 crore, up from Rs 907 crore in Q1 of FY20, its US revenues fell by 1% to Rs 373 crore

Trading ideas by Religare Broking: Buy IGL, Torrent Pharmaceuticals

IGL has tested the major support zone of the long-term moving average (200 EMA) on the daily chart of late

India growth crucial for Torrent Pharma's health amid steep fall in volume

The country accounts for 44% of overall revenues

Torrent Pharma says promoters haven't pledged equity, NSE action not needed

Torrent said a pledge of shares is a security interest in favour of lenders and can be enforced by sale of such shares in event of default

Torrent Pharma gets shareholder nod to raise up to Rs 5,000 crore

The approval of the shareholders was sought by way of special resolution through a postal ballot

Derivatives strategy on Torrent Pharmaceuticals by HDFC Securities

Derivative strategy on Pidilite Industries by Vinay Rajani -Technical and Derivatives analyst, HDFC Securities.

Torrent Pharma Q3 result: PBT rises 16% to Rs 319 crore, revenue declines

US business down by 22% in third quarter, India revenues grow by 5%

Torrent Pharma rebounds 9% from day's low on heavy volumes

The US Food and Drug Administration (USFDA) has issued a warning letter to Torrent Pharma's Indrad (Gujarat) API and formulations facility.

Torrent Pharmaceuticals manages to improve Unichem's FY19 profits

Losar comprised almost 20% of the acquired portfolio of Unichem

Strong domestic business shot in the arm for Torrent Pharma stock

Turnaround of acquired Unichem biz, improving margins, and large brands to aid earnings